New Data | Amplia’s ongoing ACCENT clinical trial in advanced pancreatic cancer has recorded an additional confirmed partial response and one unconfirmed partial response. Read the ASX release: bit.ly/3IQavFG
$ATX $INNMF #Amplia #clinicaltrial #pancreaticcancer #innovation #pharma

Amplia has announced that it has received Australian ethics approval for the Ph2 trial of narmafotinib in combination with FOLFIRINOX in advanced pancreatic cancer.
Read the ASX release: bit.ly/ATX_AU_Ethics

$ATX #Amplia #clinicaltrials #pancreaticcancer #cancertherapeutics

Amplia Therapeutics has today announced the appointment of experienced oncologist and clinical trials specialist Dr Jason Lickliter MBBS, FRACP as Chief Medical Officer. Read the ASX Release: ampliatx.com/announcement...

#Amplia #pharma #clinicaltrials #cancer #oncology

Looking forward to attending #BioKorea2025 in Seoul next week to present at the Global BIO Connection Session and meet with collaborators and potential partners.

Very pleased that Amplia could support the poster session at the ANZGOG 2025 scientific meeting. #ATX #ovariancancer

Really enjoying the Australia New Zealand Gynaecological Oncology Group (ANZGOG) Annual Scientific Meeting. Great to connect with super collaborator Gwo Yaw Ho as well! #ANZGOG2025ASM #ovariancancer #ATX

Congratulations to Dr Anne-Laure Puaux from @wehi-research.bsky.social for being awarded BioMelbourne’s Emerging Leadership Award. #biomelbwomen

Today - on World Cancer Day - we're grateful to our research collaborators, whose expertise and dedication make our clinical trials possible. Equal gratitude goes to the trial participants, and their families, who share our hope of improving outcomes for patients. #WorldCancerDay #pancreaticcancer

MILESTONE | Amplia Therapeutics has completed the planned enrolment of the ACCENT Phase 2a clinical trial, with full recruitment achieved two months ahead of schedule. Read the ASX release: www.ampliatx.com/pdf/f61a6ac4...

$ATX #clinicaltrial #pancreaticcancer #cancer #innovation

Great to have Amplia's Director of Translational Science, Dr Terrie-Anne Cock, present a poster at the Keystone TME meeting. Also present, our amazing collaborator Dr Kendelle Murphy from the Garvan @garvaninstitute.bsky.social #KSMetastasis25 #pancreaticcancer

Great to be visiting collaborators at UCSD Moores Cancer Center discussing narmafotinib and clinical potential in ovarian cancer.

Great to be visiting collaborators at UCSD Moores Cancer Center discussing narmafotinib and clinical potential in ovarian cancer.

At JPM25 in San Francisco. Lots of meetings with potential investors, partners and suppliers. Presenting our promising data from ongoing ACCENT trial in pancreatic cancer.